CV9201 targets five TAAs specifically linked to NSCLC, whereas CV9202 is a self-adjuvating mRNA vaccine that targets six antigens commonly expressed in NSCLC (NY-ESO-1, MAGEC1, MAGEC2, 5 T4, survivin, and MUC1) (243). The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.